This does happen. The FDA investigator prepares an establishment inspection report (EIR)
which summarizes the observations made at the laboratory and which contains exhibits
concerning the studies audited (Protocols, SOPs, CV’s, etc.). The EIR is then reviewed by
District personnel as well as headquarters personnel. This review may reveal additional
GLP deviations that should be and are communicated to laboratory management.